{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:32:09Z","timestamp":1793172729914,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T00:00:00Z","timestamp":1516579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple case reports suggest that olmesartan may be linked to sprue\u2010like enteropathy; however, few epidemiological studies have examined this association and results have been mixed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess whether olmesartan is associated with a higher rate of enteropathy vs other angiotensin <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> receptor blockers (<jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study among <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content> initiators in 5 <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> claims databases representing different health insurance programmes. Cox regression models were used to estimate hazard ratios (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>s) and 95% confidence intervals (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>s) for enteropathy\u2010related outcomes, including coeliac disease, malabsorption, concomitant diagnoses of diarrhoea and weight loss, and non\u2010infectious enteropathy, comparing olmesartan initiators to initiators of other <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>s after propensity score (<jats:styled-content style=\"fixed-case\">PS<\/jats:styled-content>) matching.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 1\u00a0928\u00a0469 eligible patients. The unadjusted incidence rates were 0.82, 1.41, 1.66 and 29.20 per 1000 person\u2010years for coeliac disease, malabsorption, concomitant diagnoses of diarrhoea and weight loss, and non\u2010infectious enteropathy respectively. <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>s after <jats:styled-content style=\"fixed-case\">PS<\/jats:styled-content> matching comparing olmesartan to other <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>s were 1.21 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.05\u20101.40), 1.00 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.88\u20101.13), 1.22 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.10\u20101.36) and 1.04 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.01\u20101.07) for each outcome. <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>s were larger for patients aged 65\u00a0years and older (eg for coeliac disease, 1.57 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.20\u20102.05]), for patients receiving treatment for more than 1\u00a0year (1.62 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.24\u20102.12]), and for patients receiving higher cumulative olmesartan doses (1.78 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.33\u20102.37]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This large\u2010scale, multi\u2010database study found a higher rate of enteropathy in olmesartan initiators as compared to initiators of other <jats:styled-content style=\"fixed-case\">ARB<\/jats:styled-content>s, although the absolute incidence rate was low in both groups.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14518","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T03:56:44Z","timestamp":1516679804000},"page":"792-800","source":"Crossref","is-referenced-by-count":31,"title":["Use of olmesartan and enteropathy outcomes: a multi\u2010database study"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0748-7993","authenticated-orcid":false,"given":"Y.\u2010H.","family":"Dong","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA"},{"name":"Faculty of Pharmacy School of Pharmaceutical Science National Yang\u2010Ming University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. N.","family":"Tsacogianis","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"He","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.\u2010H.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Hepato\u2010Gastroenterology Chi Mei Medical Center Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Gagne","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868090-00003"},{"key":"e_1_2_7_4_1","unstructured":"FDA Center for Drug Evaluation and Research Office of Surveillance and Epidemiology.Benicar\u00ae(olmesartan medoxomil) pediatric post marketing drug utilization review.http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM288663.pdf. Accessed February 28 2016."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868090-00005"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.12.023"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.10.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071600"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1561"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.45"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12937"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-014-0506-7"},{"key":"e_1_2_7_14_1","first-page":"47","article-title":"Olmesartan and drug\u2010induced enteropathy","volume":"39","author":"Tran TH","year":"2014","journal-title":"P T"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.09.014"},{"key":"e_1_2_7_16_1","first-page":"618071","article-title":"Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea","volume":"2013","author":"Dreifuss SE","year":"2013","journal-title":"Case Rep Gastrointest Med"},{"key":"e_1_2_7_17_1","first-page":"494098","article-title":"Olmesartan associated sprue\u2010like enteropathy and colon perforation","volume":"2014","author":"Abdelghany M","year":"2014","journal-title":"Case Rep Gastrointest Med"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12780"},{"key":"e_1_2_7_19_1","unstructured":"FDA.FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue\u2010like enteropathy) linked to blood pressure medicine olmesartan medoxomil.http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm359477.htm. Accessed February 28 2016."},{"key":"e_1_2_7_20_1","unstructured":"FDA's Mini\u2010Sentinel pilot of the Sentinel Initiative.Angiotensin II receptor blockers and celiac disease.https:\/\/www.sentinelsystem.org\/sites\/default\/files\/Drugs\/Assessments\/Mini-Sentinel_Angiotensin-II-Receptor-Blockers-and-Celiac-Disease_0.pdf. Accessed February 28 2016."},{"key":"e_1_2_7_21_1","unstructured":"FDA's Mini\u2010Sentinel pilot of the Sentinel Initiative.ARBs HCTZ atenolol amlodipine and celiac disease.https:\/\/www.sentinelsystem.org\/sites\/default\/files\/Drugs\/Assessments\/Mini-Sentinel_Modular-Program-Report_MSY3_MPR34_ARBs-HCTZ-Atenolol-Amlodipine-Celiac-Disease_0.pdf. Accessed February 28 2016."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12870"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12850"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2015.15"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.10.005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007994"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02855"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.05.012"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309690"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.10.004"},{"key":"e_1_2_7_31_1","unstructured":"Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA.Pharmacoepidemiology Toolbox.http:\/\/www.drugepi.org\/dope-downloads\/Accessed February 28 2016."},{"key":"e_1_2_7_32_1","first-page":"960","article-title":"Reader's guide to critical appraisal of cohort studies: 2","volume":"330","author":"Mamdani M","year":"2005","journal-title":"Assessing potential for confounding. BMJ"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31829b1bb1"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12973"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2256"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13413"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13000"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1470320309347788"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.830104"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.003"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.10.063"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.03.014"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1124287"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.11.001"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00250.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.108084"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-3-1"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.60"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00405-0"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03423.x"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.7009"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:11:46Z","timestamp":1694329906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,22]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/apt.14518"],"URL":"https:\/\/doi.org\/10.1111\/apt.14518","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,22]]}}}